ECDC study protocol for genomic-based surveillance of carbapenem-resistant and/or colistin-resistant Enterobacteriaceae at the EU level
This ECDC study protocol describes the technical requirements for implementing future EU-level genomic-based surveillance of carbapenem-resistant and/or colistin-resistant Enterobacteriaceae. It is meant to guide the consolidation of ECDC activities in relation to the molecular typing of multidrug-resistant pathogens and focus on the development of genomic typing-enhanced surveillance. It builds upon and synthesises evidence and the opinion of experts in Member States and at ECDC compiled since 2014.
The protocol was updated in July 2018 with minor changes to certain definitions and incorporates feedback received during a consultation with national technical coordinators at the inaugural meeting for the survey in November 2017.
Carbapenem resistant Enterobacteriaceae - second update
27 Sep 2019 - Carbapenem resistance in Enterobacteriaceae such as Klebsiella pneumoniae and Escherichia coli poses a significant threat to patients and healthcare systems in all European Union/European Economic Area (EU/EEA) countries. Carbapenem-resistant Enterobacteriaceae (CRE) infections are associated with high mortality, primarily due to delays in administration of effective treatment and the limited availability of treatment options.
Rapid risk assessment: Regional outbreak of New Delhi metallo-betalactamase-producing carbapenem-resistant Enterobacteriaceae, Italy, 2018–2019
4 Jun 2019 - A large outbreak of New Delhi metallo-beta-lactamase (NDM)-producing carbapenem-resistant Enterobacteriaceae (CRE) has been reported from the Tuscany region in Italy. Between November 2018 and May 2019, seven Tuscan hospitals notified a total of 350 cases.